Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of Orismilast in Adults With Moderate to Severe Atopic Dermatitis

NCT05469464 is registered in ClinicalTrials.gov with UNION therapeutics as lead sponsor.

NCT NCT05469464
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05469464 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of Orismilast in Adults With Moderate to Severe Atopic Dermatitis
Lead sponsor
UNION therapeutics
Phase
Phase 2
Overall status
Completed
Start date
July 11, 2022
Completion date
February 15, 2024
Enrollment
235 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis, skin diseases